[Etidronate and calcitonin to PTH (1-84) in postmenopausal osteoporosis].
Postmenopausal osteoporosis is now a major health problem. The advancement of knowledge on the role preferred cellular osteocytes, osteoblasts and osteoclasts in bone tissue, the biochemical activity and gene expression, interaction with physical activity, diet and nutritional measures, as well as various currently available drugs are disclosed in interaction with clinical studies of etidronate and calcitonin, parathyroid hormone and recombinant 1-84. It is concluded in relation to its activity at eighteen months of the administration and its assessment by bone mineral density, biochemical markers and production of fractures.
Luis Pablo
LP
Rodríguez Rodríguez
D000368:Aged; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D002116:Calcitonin / Q000627:therapeutic use*; D012968:Etidronic Acid / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*; D010281:Parathyroid Hormone / Q000627:therapeutic use*
D050071:Bone Density Conservation Agents; D010281:Parathyroid Hormone; D002116:Calcitonin; D012968:Etidronic Acid